Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Niagen Bioscience (NAGE) over the last 17 years, with Q3 2025 value amounting to $17.7 million.

  • Niagen Bioscience's Operating Expenses rose 2086.35% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 805.13%. This contributed to the annual value of $53.9 million for FY2024, which is 446.8% down from last year.
  • Niagen Bioscience's Operating Expenses amounted to $17.7 million in Q3 2025, which was up 2086.35% from $17.0 million recorded in Q2 2025.
  • Niagen Bioscience's Operating Expenses' 5-year high stood at $19.4 million during Q3 2021, with a 5-year trough of $11.1 million in Q4 2024.
  • For the 5-year period, Niagen Bioscience's Operating Expenses averaged around $15.2 million, with its median value being $14.7 million (2023).
  • Per our database at Business Quant, Niagen Bioscience's Operating Expenses skyrocketed by 5350.99% in 2021 and then crashed by 3165.46% in 2022.
  • Over the past 5 years, Niagen Bioscience's Operating Expenses (Quarter) stood at $16.2 million in 2021, then fell by 16.83% to $13.5 million in 2022, then dropped by 2.64% to $13.1 million in 2023, then fell by 15.41% to $11.1 million in 2024, then skyrocketed by 59.59% to $17.7 million in 2025.
  • Its last three reported values are $17.7 million in Q3 2025, $17.0 million for Q2 2025, and $14.6 million during Q1 2025.